Last reviewed · How we verify
Aprotinin (inhaled)
Aprotinin is a serine protease inhibitor that blocks multiple coagulation and fibrinolytic enzymes to reduce bleeding and inflammation in the lungs.
Aprotinin is a serine protease inhibitor that blocks multiple coagulation and fibrinolytic enzymes to reduce bleeding and inflammation in the lungs. Used for Cystic fibrosis (inhaled formulation in phase 3 development).
At a glance
| Generic name | Aprotinin (inhaled) |
|---|---|
| Sponsor | Fundacion del Hospital Nacional de Paraplejicos para la Investigacion y la Integracion |
| Drug class | Serine protease inhibitor |
| Target | Kallikrein, plasmin, trypsin, and other serine proteases |
| Modality | Small molecule |
| Therapeutic area | Pulmonary/Respiratory |
| Phase | Phase 3 |
Mechanism of action
Aprotinin inhibits kallikrein, plasmin, and other proteases involved in the coagulation cascade and fibrinolysis. When inhaled, it is intended to reduce excessive protease activity in the lungs, potentially decreasing inflammation, bleeding, and tissue damage in respiratory conditions. This mechanism may help preserve lung function and reduce complications in conditions characterized by excessive proteolytic activity.
Approved indications
- Cystic fibrosis (inhaled formulation in phase 3 development)
Common side effects
- Cough
- Bronchospasm
- Airway irritation
Key clinical trials
- Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment (PHASE3)
- An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: